<DOC>
	<DOCNO>NCT01788449</DOCNO>
	<brief_summary>Assess efficacy piperacillin/tazobactam reduce case colonization infection bacteria .</brief_summary>
	<brief_title>Study Evaluating Association Antibiotic Measures Control Bacterial Resistance</brief_title>
	<detailed_description>Primarily , study design ass efficacy piperacillin/tazobactam reduce case colonization infection extended-spectrum betalactamases ( ESBLs ) produce E.coli K pneumoniae , S aureus methicillin resistant ( MRSA ) Enterococcus vancomycin resistant ( VRE ) . Secondly , study plan determine acquisition rate ESBL produce E Coli K pneumoniae , methicillin resistant S Aureus ( MRSA ) vancomycin resistant Enterococcus spp ( VRE ) , pre- post-intervention .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>All patient admit ICU enrol ( qualify treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Antibiotic Bacterial Resistance</keyword>
</DOC>